Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBLE-CRC: Neoadjuvant Zanzalintinib and Retifanlimab in pMMR Colon Cancer
NCT07677579Phase 2Not yet recruiting
- Sponsor
- Northwell Health
- Start
- Aug 2026
- Primary completion
- Aug 2028
01
Overview
A Phase 2 trial of zanzalintinib, retifanlimab in colon cancer, sponsored by Northwell Health. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
zanzalintinibretifanlimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07677579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07677579.